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Abstract
Background: p53 is the most studied tumor suppressor and its overexpression may or may not cause cell death
depending upon the genetic background of the cells. p53 is degraded by human papillomavirus (HPV) E6 protein
in cervical carcinoma. Several stress activated kinases are known to phosphorylate p53 and, among them cyclin
dependent kinase 5 (Cdk5) is one of the kinase studied in neuronal cell system. Recently, the involvement of Cdk5
in phosphorylating p53 has been shown in certain cancer types. Phosphorylation at specific serine residues in p53
is essential for it to cause cell growth inhibition. Activation of p53 under non stress conditions is poorly
understood. Therefore, the activation of p53 and detection of upstream kinases that phosphorylate non-
genotoxically overexpressed p53 will be of therapeutic importance for cancer treatment.
Results: To determine the non-genotoxic effect of p53; Tet-On system was utilized and p53 inducible HPV-positive
HeLa cells were developed. p53 overexpression in HPV-positive cells did not induce cell cycle arrest or apoptosis.
However, we demonstrate that overexpressed p53 can be activated to upregulate p21 and Bax which causes G2
arrest and apoptosis, by inhibiting protein phosphatase 2A. Additionally, we report that the upstream kinase cyclin
dependent kinase 5 interacts with p53 to phosphorylate it at Serine20 and Serine46 residues thereby promoting its
recruitment on p21 and bax promoters. Upregulation and translocation of Bax causes apoptosis through intrinsic
mitochondrial pathway. Interestingly, overexpressed activated p53 specifically inhibits cell-growth and causes
regression in vivo tumor growth as well.
Conclusion: Present study details the mechanism of activation of p53 and puts forth the possibility of p53 gene
therapy to work in HPV positive cervical carcinoma.
Background
p53, a major tumor suppressor or guardian of the gen-
ome is mutated, deleted or inactivated in various can-
cers [1-4]. Almost all human papillomavirus (HPV)
infected cancer cells contain wild-type p53. p53 is non-
functional as HPVE6 protein abrogates its function
either by ubiquitin-dependent and independent degrada-
tion [5], by inhibition of acetylation or by repressing
p53-dependent downstream molecular pathways [6].
Though, E6 associates with p53 for its degradation [4];
there are contradictory reports on the inhibition and
activation of p53 pathways by E6 [7,8].
Ectopic expression of p53 in cancer cells lacking p53
or harboring mutant and/or abrogated wild-type p53,
have contrasting effects on cell-fate. In p53 null cancer
cells, p53 overexpression causes cell cycle arrest and
apoptosis [9]. However, in virus infected cells harboring
wild-type p53, overexpression of p53 does not induce
cell cycle arrest and apoptosis [10]. Till date there are
only three reports describing the consequences of p53
overexpression in HPV-positive cells and results
obtained leave ample scope for debate [10-12]. Disparity
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noviral multiplicity of infection. Taken together, the role
of p53 overexpression in HPV-positive cells remains
obscure. In HPV-positive cells, E6 works at different
hierarchal levels in p53 pathway. It degrades p53, p21
and Bax causing impairment in cell cycle arrest/apopto-
sis [13,14] and making p53 activation more difficult.
With recent developments in efficient gene delivery
systems and the prospect of gene therapy making a
come-back [15] it’s likely that p53 based therapy may
become a reality [2]. p53 executes its tumor suppressor
activity by triggering cell cycle arrest and apoptosis.
However, the factors that facilitate selection between
cell cycle arrest and/or apoptosis are not well-under-
stood. It has been reported that p21 is most important
transcriptional targets of p53 for causing cell cycle arrest
[16] and p53 executes apoptosis through Bax transcrip-
tion [17]. To study the role of p53 in E6-positive cells,
we developed a novel isogenic HeLa cells with Tet-On-
regulated p53 expression. Tet-On system exhibits tight-
on/off regulation and is devoid of pleiotropic effects.
Moreover, rapidly high induction levels are achievable
and the inducer, doxycycline (Dox), is well-
characterized.
p53 overexpression does not promote cell cycle arrest
and apoptosis in HeLa cells. We demonstrate that pro-
tein phosphatase 2A (PP2A) controls p53 functions and
its inhibition activates p53, causing cell cycle arrest/
apoptosis in vitro and tumor growth inhibition in vivo.
Interestingly, cyclin dependent kinase 5 (Cdk5) regulates
p53 phosphorylation essential for its activation. Taken
together, we propose that non-genotoxically overex-
pressed p53 can be activated by inhibiting its depho-
sphorylation in HPV-positive cervical cancer cells. This
strategy may be of therapeutic importance in p53 asso-
ciated gene therapy [18-20].
Materials and methods
Chemicals and cell-lines
Antibodies against p53 (DO-1 and FL-393), GFP, pCdk5,
Cdk5, p35, Bcl-2, cytochrome-C, PARP, COX-IV, b-
Tubulin, b-Actin, HRP-linked secondary antibodies,
Control, p53 and PP2A siRNAs were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-
specific p53 antibodies were purchased from Cell Signal-
ling Technology (Danvers,M A ) .F I T Ca n dr h o d a m i n e -
conjugated secondary antibodies were purchased from
KPL (Gaithersburg, MD). APO-Direct TUNEL kit,
Matrigel and Bax antibody was purchased from BD
(Franklin Lakes, NJ). Dox was purchased from Sigma
(St. Louis, MO). Hygromycin B and Tet system
approved serum was purchased from Clontech (Moun-
t a i nV i e w ,C A ) .G 4 1 8a n dM T Tw e r ep u r c h a s e df r o m
USB (Cleveland, OH). Okadaic acid (OA), mitotracker
dye, DMEM, FBS and Lipofectamine2000 were pur-
chased from Invitrogen (Carlsbad, CA). Cdk2/5 inhibi-
tor, PFTa and U0126 were purchased from Calbiochem
(Gibbstown, NJ). Cdk5 siRNA was purchased from
Dharmacon Inc (Lafayette, CO). Development of cell-
lines is described in additional file 1.
Plasmids and transfection
pC53-SN3 and pG13CAT were a kind gift from Dr. Bert
Vogelstein, John Hopkins, Baltimore, MD. p53 fragment
of pC53-SN3 was sub cloned in BamH1 site of pTRE
and renamed as pTREp53. pG13CAT contains 13
repeats of p53 consensus binding site inserted in the 5’
end to polyomavirus basal promoter linked to CAT
reporter gene. Cells were co-transfected with 2 μgo f
pG13CAT and 0.5 μg of pEGFPC1 which serves as an
internal control for transfection. Bcl-2 fragment from
pRc/CMVBcl-2 (kind gift from Dr. S. Soddu, Regina
Elena Cancer Institute, Italy) was excised by HindIII and
cloned into pTRE2 to obtain pTRE2Bcl-2. Cells were
transfected with either 2.0 μg( f o r3 5m mp l a t e )o r0 . 5
μg (for 96 well plate) plasmid by Lipofectamine2000
transfection reagent as per manufacturer’s instructions.
Clonogenic-survival assay
Cells (500) were treated with indicated concentrations of
Dox, OA or Cdk2/5 inhibitor based on the experimental
design and incubated for 48 h. Cells were further grown
for 21 days and thereafter colonies on the plate were
stained with crystal-voilet.
Electrophoretic mobility shift assay (EMSA)
To visualize the DNA-binding activity of p53 in nuclear
extracts of HTet23p53, HTet26p53, HTet43GFP and
HeLa cells, EMSA was performed. After treatment with
Dox, cells were harvested for the preparation of cyto-
plasmic and nuclear fractions by using nuclear extrac-
tion kit as per manufacturer’si n s t r u c t i o n s( C h e m i c o n ,
Billerica, MA). Nuclear lysates were incubated for 45
min at 4°C and cleared by centrifugation at 15,000 ×g
for 15 min at 4°C. Equal amount of nuclear proteins
were used for the binding reaction. Complementary oli-
gonucleotides containing the sequences corresponding
to putative p53 binding site (forward, 5′-GAACATGTC-
TAAGCATGCTG-3′;r e v e r s e ,5 ′-CAGCATTCTTAGA-
CATGTTC-3′) were annealed and 5′-end-labeled with
2 micro curie (ΔCi) [g-
32P] ATP using 10 U of T4 poly-
nucleotide kinase (Invitrogen) for 90 min. Binding reac-
tion was carried out in a final volume of 20 μl
consisting of 10 mM Tris.HCl (pH 7.5), 50 mM NaCl,
1 mM DTT, 1 mM EDTA, 2.5% glycerol, 1 μg deoxyino-
sinic deoxycytidylic acid [poly(dI-dC)], 300 ng BSA, 5 μg
nuclear extract, and 2 μlo f[ g-32P] labeled oligonucleo-
tide probe. Reaction mixtures were incubated for 20 min
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polyacrylamide gel. Gel was dried under vacuum at 80°C
for 45 min by gel dryer (Bio-Rad) and DNA-protein com-
plex were visualized by autoradiography.
Chloramphenicol acetyl transferase assay
Cells were co-transfected with pG13CAT and pEGFPC1
expression vector using Lipofectamine2000 as described
in transfection section. After 18 h post-transfection, p53
was induced with Dox for 48 h with or without PFTa
pretreatment for 1 h. CAT assay was performed as
described earlier [2] except that the reaction time was
reduced to 30 min at 37°C. Spots were quantified by
phosphoimager (Bio-Rad). GFP intensity was directly
measured from the cell lysates to check or correct for
equal transfection efficiency as well to normalize the
reporter activity. The fluorescence intensity of GFP in
equal amount of lysate was measured by fluorimeter
(Fluoroskan Ascent FL, Fisher Scientific) with excitation
at 485 nm and emission at 510 nm.
SiRNA transfections
Cells were transfected with 100 nM control or p53
siRNA using Lipofectamine2000 [21]. Eighteen hour
post-transfection, Dox was added with or without OA
and further incubated for 48 h. Thereafter, western blot
or MTT assay was performed. To knock-down PP2A
and Cdk5; Cdk5 siRNA was transfected 12 h prior to
PP2A siRNA transfection and then incubated with Dox
for 48 h.
Immunoprecipitation and Chromatin-immunoprecipitation
(ChIP) assay
After indicated treatment cells were lysed in RIPA buf-
fer. Equal amount of protein (400 μg) was taken and
lysates were pre-cleared with 50 μl protein A/G-plus
agarose for 30 min. Fifty microgram lysates were run as
input. Agarose beads were pelleted and supernatant was
incubated with p53 specific antibody overnight at 4°C.
Fifty microliter protein A/G-plus agarose was added in
antibody-antigen complex with gentle shaking for 4 h at
4°C. The protein A/G-plus was separated by centrifuga-
tion at 4,000 rpm. Target and its associated proteins
were disrupted and resolved on SDS-PAGE. The expres-
sion of Cdk5 and p53 was detected by western blotting.
For chromatin-immunoprecipitation assay cells or
homogenized tumors which were earlier fixed with 1%
para-formaldehyde for 15 min, were lysed with 500 μlo f
lysis buffer [5 mM PIPES (pH 8.0), 85 mM KCl and 1%
NP-40]. After centrifugation (5000 rpm), nuclear pellets
were resuspended in 150 μl buffer [50 mM Tris-Cl (pH
8.0), 10 mM EDTA and 1% NP-40]. To fragment DNA
to approximately 500 bps, samples were sonicated and
centrifuged for 10 min. Samples were diluted 10-fold in
IP buffer [16.7 mM Tris-Cl (pH 8.0), 167 mM NaCl, 1%
N P - 4 0a n d1m ME D T A ] .S a m p l e s( 4 0 0μg) were incu-
bated with anti-p53 or anti-goat IgG overnight. Remain-
ing solutions (10-times diluted) were used as input.
Protein A/G-plus agarose beads pre-blocked with sal-
mon-sperm DNA were added to antibody-antigen com-
plexes and incubated for 4 h. Immune-complexes were
centrifuged and washed with buffer [20 mM Tris-Cl (pH
8.0), 150 mM NaCl, 0.5% SDS, 1% Triton X-100 and 2
mM EDTA] twice and with buffer containing 250 mM
NaCl. Immune-complexes were eluted by 50 μl of buffer
[1% SDS and 0.1 M NaHCO3] twice. Then 20 μlo f5M
NaCl was added and incubated at 65°C overnight. DNA
was precipitated with ethanol. RT-PCR was performed
with promoter primer pairs for p21 (F) 5′-GGC TGG
TGG CTA TTT TGT CC-3′,( R )5 ′-TCC CCT TCC
TCC CTG AAA AC-3′, and bax (F) 5′-AGC GTT CCC
CTA GCC TCT TT-3′ and (R) 5′-GCT GGG CCT GTA
TCC TAC ATT CT-3′ at annealing temperature 57°C
and 59°C respectively.
Mitochondrial and cytosolic fractionation
HTet26p53 cells were swelled in ice-cold hypotonic
HEPES buffer [10 mM HEPES (pH 7.4) 5 mM MgCl2,
40 mM KCl, 1 mM PMSF and protease inhibitor cock-
tail] for 30 min and centrifuged at 1500 rpm to pellet
the nuclei. The resulting supernatant was centrifuged at
10,000 rpm to pellet mitochondrial fraction. Supernatant
was used as cytosolic fraction and mitochondrial pellet
was washed with PBS twice. This pellet was lysed in
mitochondrial buffer [10 mM MOPS (pH 7.4), 1 mM
EDTA, and 4 mM KH2PO4, 1% NP-40, protease inhibi-
tor cocktail] and centrifuged at 12,000 rpm for 30 min.
Immunostaining
Cells grown on Labtek chamber slides were treated with
Dox for 48 h and processed for immunofluorescene
study as described earlier [21]. Primary antibody against
p53 (1:50) was added and incubated for 2 h at room
temperature. Following incubation, cells were washed 5
times. Fluorescein isothiocyanate (FITC) or Rhodamine
conjugated secondary antibodies (1:100) were added and
incubated for 1 h at room temperature. After five
washes, vectashield mounting medium containing DAPI
was added and slides were examined by a confocal
microscope (LSM510, Carl Zeiss, Germany). For mito-
tracker deep red staining, after indicated treatments
cells were incubated with 200 μM of mitotracker dye for
20 min. These were then fixed and processed for immu-
nofluorescence study by incubating with a Bax specific
primary antibody and FITC conjugated secondary anti-
body. Slides were mounted with DAPI containing med-
ium and images were acquired in confocal microscope.
Terminal deoxynucleotidyltransferase dUTP nick end
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facturer’s protocol (BD) except the reaction time was
increased to 3 h at room temperature. Cells were
washed twice with binding buffer and PI solution was
added. Slides were washed, mounted and observed
under confocal microscope (META, Carl Zeiss).
Tumor growth
HTet23p53 or HTet43GFP cells (5 × 10
6)i n1 0 0μlP B S
mixed with 100 μl matrigel were injected s.c. into 4-6
week-old female NOD/SCID mice (Jackson Labora-
tories). Total 12 mice were injected with HTet23p53
cells on the right flank and 4 mice were injected with
HTet43GFP cells on both the flanks. Out of two groups,
one was fed on 500 ng/ml Dox in drinking water.
Tumor development was monitored. After tumor-size
reached to 5-10 mm in diameter, OA (40 pg/mice) was
administered at the tumor site. Tumor-sizes were mea-
sured weekly by digital Vernier Caliper (Sigma) and
tumor volume was calculated by formula V = [1/2 ×
(large diameter) × (small diameter)
2.
MTT assay, FACS analysis and western blotting
For methylthiazole tetrazolium (MTT) assay, 7,500 cells
were treated with Dox, OA and/or Cdk2/5 inhibitor as
per experimental requirement and assayed for cell survi-
val. For western blotting following indicated treatments,
cells were washed thrice with ice-cold phosphate buffered
saline (PBS) and lysed in ice-cold lysis buffer (50 mM
Tris-Cl, pH 7.5, with 120 mM NaCl, 10 mM NaF, 10 mM
sodium pyrophosphate, 2 mM EDTA, 1 mM Na3VO4,1
mM PMSF, 1% NP-40 and protease inhibitor cocktail
(Roche Diagnostics, Penzberg, Germany). Equal amount
of protein was resolved on a polyacrylamide gel. Where
ever possible blots were stripped by incubating the mem-
branes at 50°C for 30 min in stripping buffer (62.5 mM
Tris-Cl pH 6.7, 100 mM mercaptoethanol, 2% SDS) with
intermittent shaking. Membranes were washed thor-
oughly with TBS and reprobed with required antibodies.
Otherwise gels run in duplicates were probed for the
desired proteins by western blotting and then compiled.
For FACS analysis cells were plated at a density of
5×1 0
5 cells in 35 mm plates and allowed to adhere for
24 h. Cells treated as per experimental requirement
were harvested by trypsinization and processed for flow
cytometric analysis. The fluorescence of propidium
iodide (PI) was measured through a 585 nm filter in a
flowcytometer (FACS Calibur, BD) for 10,000 cells. Data
were analyzed using cell quest software (BD). Details of
these are as published earlier [21,22].
TUNEL staining
To detect apoptotic cells APO-DIRECT TUNEL assay
kit (BD) was used followed by flow cytometric analysis
as per the manufacturer’s instructions with some modi-
fications. Cells were incubated in DNA-labeling solution
for 2 h at 37°C and analyzed by FACS Calibur (BD). PI
stains total DNA and FITC conjugated dUTP stains
apoptotic cells.
Reverse-Transcription-PCR
Total RNA from the cells or tumor samples was
extracted using TRIzol™ reagent and PCR was per-
formed as described [21] with following primers; p53 (F)
5-CTG AGG TTG GCT CTG ACT GTA CCA CCA
TCC-3′,( R )5 ′-CTC ATT CAG CTC TCG GAA CAT
CTC GAA GC-3′;e 6( F )5 ′-TGT GTA TGG AGA CAC
ATT GG-3′,( R )5 ′-ATA GTG CCC AGC TAT GTT
GT-3′; b-actin (F) 5′-ATC TGG CAC CAC ACC TTC
TAC AAT GAG CTG CG-3′, (R) CGT CAT ACT CCT
G C TT G CT G AT C CA C AT C TG C - 3 ′, at annealing
temperature of 55°C and p21 (F) 5′-GGC GTT TGG
AGT GGT AGA AA-3′ (R) 5′-GAC ACC ACT GGA
GGG TGA CT-3′ at annealing temperature of 59°C for
25-30 cycles.
Statistical analysis
Statistical comparisons are made using student’sp a i r e d
t-test using SPSS10.0 (SPSS Inc., IL) and P-value < 0.05
was considered significant.
Results
Development and screening of HeLaTet-On p53 inducible
cell-system
Seven out of 24 p53 transfected clones (HeLaTet-On-
p53 21 to 44) and nine out of 12 GFP transfected clones
(HeLaTet-On-pBIEGFP 41 to 52) exhibited induction in
the presence of Dox (see Additional file 2A and 2B).
Two clones HeLaTet-On-p53-23 S and HeLaTet-On-
p53-26 S (represented as HTet23p53 and HTet26p53)
along with HeLaTet-On-BIEGFP-43 (represented as
HTet43GFP) with low-leaky and high regulatory expres-
sion were selected for further studies. Growth properties
of clones for 6 days were similar to parental HeLa cells
(see Additional file 3A). Also, protein concentration did
not alter between the clones and the parental cells (see
Additional file 3B). Dox upto 2000 ng/ml was non-toxic
(see Additional file 3C).
Tight-regulation of p53 expression was confirmed by
addition of 100 and 1000 ng/ml of Dox. p53 expression
was induced in response to Dox in a dose-dependent
manner (Figure 1A). Also, GFP protein expression was
tightly-regulated (Figure 1B). As E6 downregulation
induces cell-death, E6 mRNA levels in p53 and GFP
expressing clones as well as in parental HeLa cells was
detected by RT-PCR. No alteration in e6 expression fol-
lowing treatment with Dox was observed (Figure 1C).
p53 localization and nuclear retention is essential for
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activities. However, in cancer cells wild-type p53 is
sequestered in cytoplasm by various molecules which
prevent its functioning [23]. p53 induced in response to
Dox in a dose dependent manner is predominantly loca-
lized in the nucleus (green represents p53 staining and
blue represents DAPI for DNA stain in the nucleus)
(see Additional file 4A and 4B). No alteration in p53
protein expression was detected in Dox treated
HTet43GFP (red-staining) and parental HeLa cells
(green-staining) (see Additional file 4C and 4D). In
HTet43GFP cells GFP protein expression (green-stain-
ing) is tightly-regulated by Dox (see Additional file 4C).
p53 overexpression does not cause cell cycle arrest or
growth inhibition in HeLa cells even though it possesses
DNA binding activity
PI staining for the cell cycle analysis depicted no altera-
tion in cell cycle phases in p53 overexpressing cells as
compared to HTet43GFP or HeLa cells (Figure 2A).
Long-term consequence of p53 overexpression was
investigated by clonogenic-survival assay. Almost equal
numbered and sized colonies were formed by p53 over-
expressing HTet23p53 and HTet26p53 cells (Figure 2B).
As Dox-induced p53 was localized in the nucleus, its
in vitro DNA-binding activity by electrophoretic mobi-
lity shift assay (EMSA) and in vivo transcriptional activ-
ity by chloramphenicol acetyl transferase (CAT) reporter
gene was evaluated. Increased binding of p53 to its con-
sensus sequence in HTet23p53 and HTet26p53 but not
in HTet43GFP and HeLa cells after Dox addition was
detected (Figure 2C). Also, there was increase in CAT
activity in p53 overexpressing HTet23p53 and
HTet26p53 cells and no increase was detected in
HTet43GFP and HeLa cells (Figure 2D). Specificity of
CAT activity was confirmed by PFTa treatment.
Activation of p53 by inhibition of phosphatase
To inhibit the phosphatase, okadaic acid (OA), a potent
and specific inhibitor of PP1A and PP2A was utilized.
Inhibitory-effect of OA for PP1A and PP2A is concen-
tration-dependent. Inhibitory-concentration (IC50)f o r
A
p53
HTet23p53      HTet26p53   HTet43GFP        HeLa
GFP
A
B
Dox (ng/ml)
β-Actin
β-Actin
p53 
high exposure
Dox (ng/ml)
C
HPV18e6
150 bp
HTet23p53      HTet26p53   HTet43GFP        HeLa
C
β-actin
834 bp
Dox (ng/ml)
Figure 1 p53/GFP are tightly regulated by Dox and it does not alter HPV18E6, a viral cell cycle deregulator. (A) Selected clones
(HTet23p53, HTet26p53 and HTet43GFP from Additional file 2) were treated with 100 and 1000 ng/ml of Dox and after 48 h cell lysates were
processed by western blotting for p53. b-Actin was used as a loading control. (B) Cells were treated as mentioned in (A) and processed for
western blotting to detect GFP. b-Actin was used as a loading control. (C) HPV18 E6 mRNA levels were determined by semi-quantitative PCR.
Cells treated with Dox were processed for RT-PCR. b-actin was used as a loading control. HTet43GFP and HeLa cells served as experimental
controls.
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We used 5 nM OA to specifically inhibit PP2A and this
concentration inhibits almost 100% of phosphatase
activity in the cells [25]. Dose-dependent growth inhibi-
tion (2.5 nM OA caused 25% whereas 5 nM caused
60%) was observed in p53 overexpressing HTet23p53
and HTet26p53 as compared to HTet43GFP and HeLa
cells (Figure 1A). OA alone did not significantly affect
cell-survival (Figure 3A). Decrease in colony number
and size in p53 overexpressing OA treated cells
(HTet23p53 and HTet26p53) was observed as compared
to HTet43GFP cells (Figure 3B). To confirm that indeed
p53 specifically inhibits cell-growth in the presence of
OA, p53 siRNA was transfected which decreased the
levels of overexpressed p53 as compared to transfection
with Ctrl siRNA (Figure 3C inset). Silencing p53 reduces
cell-death by 30-35% in p53 overexpressing cells as
compared to HTet43GFP cells or Ctrl siRNA transfected
cells (Figure 3C).
Activated p53 executes its anti-proliferative action
through cell cycle arrest and apoptosis by specific
promoter recruitment
To evaluate whether growth-inhibition is caused by cell
cycle arrest or apoptosis, cell cycle analysis was per-
formed. Approximately 10% increase in S phase and
30% increase in G2 phase in p53 overexpressing cells as
compared to GFP expressing cells was observed
(Figure 4A). p21, a p53 transcriptional target is a domi-
nant effecter molecule that causes cell cycle arrest. Its
transcript level increased significantly following OA
treatment in p53 overexpressing HTet23p53 and
Figure 2 Overexpressed p53 neither causes cell cycle arrest nor inhibits growth even though it exhibits in vitro as well as in vivo DNA
binding. (A) Cells treated with 100 and 1000 ng/ml of Dox were incubated for 48 h and processed for flow cytometric analysis by PI staining.
Graphical representation of FACS data, bar graph represents % cell populations in each cell cycle phase (± S.E.). (B) Five hundred cells seeded in 35
mm plates and treated with Dox as mentioned in (A) were allowed to grow for 21 days with replacing Dox containing medium every 4 day. Cells
in plates were stained with crystal violet stain and colonies were counted. Bar graph represents average of colony number per plate (± S.E.) from
three independent experiments. (C) For in vitro DNA binding, after 100 and 1000 ng/ml Dox treatment for 48 h, nuclear extracts derived from
HTet23p53, HTet26p53, HTet43GFP and HeLa cells were incubated with a g-
32P-labeled DNA probe having the consensus p53 binding motif. Bar
graph represents densitometric values of autoradiograph (± S.E.). (D) In vivo transactivity of p53 was determined by transfecting pG13CAT as well as
pEGFPC1 plasmid in HTet23p53, HTet26p53, HTet43GFP and HeLa cells following Dox treatment of 48 h. Percentage CAT activity was calculated by
measuring the acetylations of
14C-chloramphenicol on thin layer chromatography using phosphorimager. Percent CAT/GFP for HTet43GFP was
calculated by dividing with GFP reading for without Dox treated cells only. PFTa was used for the specificity of the p53 activity. Bar graph
represents %CAT values normalized to GFP fluorescence for transfection efficiencies from three independent experiments (± S.E.).
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Under similar experimental conditions no change in
HPV18E6 mRNA was observed (Figure 4B). TUNEL
assay using FACS analysis indicated that 40% cells were
apoptotic in p53 overexpressing HTet23p53 and
HTet26p53 cells treated with OA in comparison to 8%
in OA treated HeLa cells (see Additional file 5). Though,
DOX treatment increases p53 transcript as well as pro-
tein levels, OA treatment does not lead to further
enhancement in p53 transcript levels in HTet23p53 and
HTet26p53 cells (Figure 4B and 4C). Interestingly, OA
treatment significantly increases p53 protein levels (Fig-
ure 4C). Finally, ChIP assay was performed to ascertain
whether in p53 overexpressing OA treated cells p53 is
recruited on the promoter of its effecter genes. Results
obtained indicate that indeed in p53 overexpressing cells
treated with OA, p53 occupies both p21 and bax pro-
moters (Figure 4D).
Inhibition of Cdk5 following PP2A inhibition promotes
cell survival
The importance of kinases involved in the activation of
p53 by OA treatment was explored by utilizing specific
pharmacological inhibitors. Pre-treatment with a specific
Cdk2/5 inhibitor increases cell survival whereas ERK
inhibition by U0126 did not have any impact on survival
Figure 3 Inhibition of PP2A causes cell-growth inhibition in a p53 dependent manner. (A) HTet23p53, HTet26p53, HTet43GFP and HeLa
cells were treated with indicated concentrations of OA with or without Dox for 48 h. Thereafter MTT assay was performed. Bar represents
variation within the wells of an experiment (± S.E.). *Represents P < 0.01. (B) Five hundred cells plated were treated as mentioned in (A). After 48
h cells were washed and incubated for 21 days. Cells were stained with crystal-violet and colonies were counted. Bar graph represents average
colony number per plate (± S.E.) from three experiments. *Represents P < 0.01. (C) HTet23p53, HTet26p53, HTet43GFP and HeLa cells were
transfected with control or p53 siRNA in 96 well-plates, 18 h post-transfection cells were treated with Dox and/or OA and MTT assay was
performed after 48 h. Bar graph represents variation within the wells of an experiment (± S.E.). *Represents P < 0.05. HTet26p53 cells were
transfected with control or p53 siRNA. Eighteen hour post-transfection cells were treated with Dox and further incubated for 48 h. MTT for cell
survival evaluation or western blot analysis detection of p53 was performed.
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HTet23p53 and HTet26p53 cells as compared to
HTet43GFP and HeLa cells. To confirm the functional
importance of PP2A and Cdk5, corresponding siRNAs
were transfected into the cells. Cdk5 siRNA significantly
decreased Cdk5 protein levels (Figure 4B upper left
panel). Transfection with PP2A siRNA decreases its pro-
tein levels whereas p53 protein increases in addition to
inhibiting cell survival (Figure 4B upper right panel).
Interestingly, siRNA mediated knockdown of Cdk5 pro-
motes survival of p53 overexpressing HTet23p53 and
HTet26p53 cells as compared to HTet43GFP cells (Fig-
ure 5B). Cdk5 inhibition by its inhibitor causes signifi-
cant increase in number and colony-size of p53
overexpressing HTet23p53 and HTet26p53 cells inspite
of being treated with OA (Figure 5C). This result indi-
cates that activation of p53 is dependent on the func-
tional level of Cdk5. In p53 overexpressing cells OA
treatment causes increase in apoptotic population which
diminishes in the presence of Cdk5 inhibitor, as
detected by TUNEL immunofluorescence staining (Fig-
ure 5D). Finally, to prove that stabilization and activa-
tion of overexpressed p53 protein is dependent on the
functionality of Cdk5, cells treated with OA acid were
also exposed to Cdk2/5 inhibitor. Treatment with OA
increases the levels of overexpressed p53 whereas, addi-
tion of Cdk2/5 inhibitor diminishes it (Figure 6A).
Neither OA nor Cdk2/5 affects the level of Cdk5 protein
per se. However, the level of p35 protein decreases in
the presence of OA and addition of Cdk2/5 reverts back
to the basal level (Figure 6A). Finally Cdk5 activity was
confirmed by increased phosphorylation level of Cdk5
tyrosine 15 residue following OA treatment (Figure 6B
compare lane 2 vs lane 1) which was diminished by
Cdk2/5 inhibitor (Figure 6B compare lane 3 vs lane 1).
p53 executes apoptosis through mitochondrial pathway
Bax and Bcl-2 levels were detected to determine the
involvement of mitochondrial pathway. Though Bax was
upregulated following OA treatment, its upregulated
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Figure 4 p53 executes cell-growth inhibition by cell cycle arrest and apoptosis. (A) HTet23p53, HTet26p53 and HTet43GFP cells treated
with Dox with or without OA and were processed for cell cycle analysis. Bar graph represents average of three independent experiments (± S.
E.). *Represents P < 0.05. (B) Cells treated as mentioned in (A) were processed for RT-PCR by utilizing p53, p21, HPV18e6 and b-actin primers. (C)
HTet23p53, HTet26p53 and HTet43GFP cells were treated with Dox with or without OA for 48 h and western blot for p53 was performed. b-
Actin served as loading control. (D) ChIP assay demonstrates in vivo interaction of overexpressed p53 with the p21 and bax promoters. Cells
were treated with Dox with or without OA for 48 h and processed for ChIP assay.
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Page 8 of 15status was reverted back in the presence of Cdk2/5 inhi-
bitor in HTet23p53 and HTet26p53 cells overexpressing
p53 (Figure 7A). Complementary to Bax upregulation,
Bcl-2, which heterodimerizes and interferes with Bax
homodimerization, was downregulated and its level was
normalized back to basal expression in the presence of
Cdk2/5 inhibitor, in p53 overexpressing OA treated cells
(Figure 7A). No alterations in Bax and Bcl-2 were
observed in HTet43GFP cells. Further, to confirm that
Cdk2/5 inhibitor actually inhibits apoptosis; PARP was
detected by western blot. Cleavage of PARP into p85
peptide was detected only in p53 overexpressing
HTet23p53 and HTet26p53 cells (Figure 7A). Immuno-
fluorescence studies revealed increased mitochondrial
localization of Bax in p53 overexpressing OA treated
cells, which was diminished by Cdk2/5 inhibitor (Figure
7B). HeLa cells served as control for these studies. In
p53 overexpressing OA treated cells decreased mito-
chondrial cytochrome-C (Cyt-C) and increased cytosolic
levels were observed (Figure 7C). Finally, to ascertain
the mitochondrial apoptosis, Bcl-2, was ectopically
expressed (Figure 7D inset). As expected significant
decreased apoptotic cells were detected in p53 overex-
pressing OA treated HTet23p53 and HTet26p53 cells in
comparison to vector alone transfected or in
HTet43GFP and HeLa cells (Figure 7D).
Cdk5 interacts to phosphorylate p53
Under genotoxic stress conditions activation of p53 is
achieved by phosphorylation at Ser20 and Ser46 residues
Figure 5 Cdk5 inhibition rescues p53 overexpressing cells from OA induced cell-death. (A) HTet23p53, HTet26p53, HTet43GFP and HeLa
cells pretreated for 12 h with indicated concentrations of Cdk2/5 inhibitor or U0126 were treated with Dox in the presence or absence of OA
and further incubated for 48 h before performing MTT assay to evaluate cell-survival. Bar graph represents variation within the wells of an
experiment (± S.E.). *Represents P < 0.01. (B) HTet23p53, HTet26p53 and HTet43GFP cells plated in 96 well-plate were transfected with Ctrl or
Cdk5 siRNA and incubated for 12 h. These cells were then transfected with PP2A siRNA and further incubated with Dox for 48 h. Cells were then
processed for MTT assay. HTet23p53 cells were transfected with PP2A or Cdk5 siRNA and incubated with or without Dox for 48 h followed by
western blotting for PP2A and p53 or Cdk5 respectively (upper panel). (C) Five hundred HTet23p53, HTet26p53 and HTet43GFP cells pretreated
for 12 h with Cdk2/5 inhibitor, were treated with Dox and/or OA as mentioned in (A) and further incubated for 48 h. After 21 days cells were
stained with crystal-violet and colonies were counted. Bar graph represents average colony number (± S.E.) form three independent experiments.
*Represents P < 0.05. (D) HTet23p53, HTet26p53 and HeLa cells pretreated for 12 h with Cdk2/5 inhibitor followed by addition of Dox with or
without OA were further incubated for 48 h and processed for apoptosis detection by TUNEL assay. Bar:10 μm.
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Page 9 of 15[26,27]. To explore that in p53 overexpressing OA trea-
ted cells Cdk5 plays an important role, phosphorylation
status of Ser20 and Ser46 was detected in the presence
or absence of OA. Phosphorylation at Ser20 and Ser46
residues of overexpressed p53 increased significantly in
OA treated cells, whereas in the presence of Cdk2/5
inhibitor phosphorylated forms diminished (Figure 8A).
Under identical experimental conditions no increased
phosphorylation was detected in HTet43GFP cells.
Finally, to ascertain whether Cdk5 associates with p53
to cause its phosphorylation, co-immunoprecipitation
experiment was performed by immunoprecipitating p53
with its specific antibodies and this immuno-complex
was probed with Cdk5 antibody by western blotting as
described in materials and methods section. Interest-
ingly, Cdk5 was detected in immuno-complex isolated
from p53 overexpressing OA treated HTet26p53 cells.
In the presence of Cdk2/5 inhibitor this interaction was
reduced (Figure 8B).
Activated and not overexpressed p53 inhibits tumor
growth
To validate that these in vitro findings have in vivo
implications also, HTet23p53 or HTet43GFP cells were
administered in NOD/SCID mice and monitored weekly
for tumor growth. Up to three weeks after implanting
cells tumors grew identically in mice supplemented with
or without Dox. Thereafter, tumor growth was rapid in
mice injected with HTet23p53 cells and treated with
OA without being supplemented with Dox. Similarly, in
mice injected with HTet43GFP cells, tumors grew
rapidly in those treated with OA and supplemented with
or without Dox. Interestingly, in mice injected with
HTet23p53 cells and treated with OA,in addition to
being supplemented with Dox, tumor growth was
significantly retarded (Figure 9A). Reduced tumor-
growth is reflected in differences in size and weight of
the excised tumors (Figure 9B). Tumor samples were
analyzed to ascertain the involvement of stabilized p53
and also for the activation of its downstream growth
inhibitory factors. In tumor samples from OA treated
mice bearing HTet23p53 cells, p53 and bax protein
levels were higher (Figure 9C) and these did not
increase in tumors of HTet43GFP cells. p53 transcript
and protein levels were higher in HTet23p53 cells
derived tumors from mice supplemented with Dox and,
levels were not enhanced further by OA treatment (Fig-
ure 9D). These results clearly indicate that the stabiliza-
tion of p53 protein also occurs in in vivo tumors.
Conclusively, the ChIP assays performed on lysates of
tumors excised from mice provided with Dox in water,
with or without OA treatment revealed enhanced pro-
moter occupancy of activated p53 on p21 and bax pro-
moters in vivo (Figure 9E).
Discussion
This study highlights the activation of overexpressed
p53 and its effect on cell cycle arrest and apoptosis in
HPV-positive HeLa cells. Under stress conditions p53 is
stabilized by phosphorylation and acetylation at serine/
threonine/tyrosine and lysine residues respectively. The
serine phosphorylation at residues 6,9,15,20,33,37,46,315
and 392 plays a crucial role depending upon the nature
of stress thereby causing cell cycle arrest and/or apopto-
sis [26,27]. Unlike stress condition wherein p53 induc-
tion promotes cell cycle arrest or apoptosis, this study
demonstrates that p53 overexpression in HPV-positive
cells does not induce cell cycle arrest or apoptosis
though; it is reported to do so in other cancer cell types
[16,17,28]. The reason for this difference could be
p35
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OA (5 nM)     - +        +       - +       +       - +       +
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OA (5 nM)     - +          + 
Cdk2/5 (10 μM)     - - +
HTet23p53
F
pCdk5
Figure 6 Inhibition of Cdk5 activity reverses OA induced increase in p53 levels. (A) HTet23p53, HTet26p53 and HTet43GFP cells pretreated
for 12 h with indicated concentrations of Cdk2/5 inhibitor or U0126 were treated with Dox in the presence or absence of OA, further incubated
for 48 h and processed for western blotting with p53, Cdk5 and p35 antibodies. (B) HTet23p53 cells were treated as mentioned in (A) and
processed for western blot for pCdk5 (Tyr15) and Cdk5 specific antibodies.
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Page 10 of 15inhibition of cellular machinery necessary for perform-
ing critical posttranslational modifications which are
required for sequence specific promoter selection of the
genes responsible for the induction of cell cycle arrest
or apoptosis by HPV [5,29].
Equilibrium between phosphorylation and depho-
sphorylation of a protein like p53 is essential for its nor-
mal functioning in the cells. Therefore, conditions
causing shift in the equilibrium between phosphorylated
and non-phosphorylated states will dictate the function-
ality of a protein and subsequently the cells fate [30,31].
Protein phosphatases inactivate p53 by dephosphorylat-
ing it. Very recently Lu et al., reported that PP2A inhi-
bition also decreases p53 protein and its
phosphorylation at Ser15 through activation of its nega-
tive regulator MDM2 [32]. In contrary, we herein
demonstrate that inhibition of phosphatase stabilizes
and activates overexpressed p53 probably because of
impairment in functional MDM2 pathway in HPV-posi-
tive cells [33]. Phosphorylation of p53 at specific serine
residues is essential for the induction of cell cycle arrest
and apoptosis. Under stress conditions p53 is phos-
phorylated at Ser20 located in the transactivation
domain [26], thereby stabilizing and triggering down-
stream pathways. Ser46 phosphorylation, located in the
DNA-binding domain of p53 plays a crucial role in
sequence specific DNA-binding required for the induc-
tion of cell cycle arrest and apoptosis [34]. In this study,
w ec o n f i r mt h a tp h o s p h o r y l a tion at these residues fully
restores p53 functionality and induces cell-death even
under non-stress conditions.
Stress-induced p53 is stabilized and activated by var-
ious kinases such as ATM, ATR, Chk1, HIPK2 and
Chk2 by phosphorylation [26,27,34,35]. However, very
Figure 7 p53-mediated apoptosis follows intrinsic mitochondrial pathway. (A) HTet23p53, HTet26p53 and HTet43GFP cells pretreated for 12
h with Cdk2/5 inhibitor followed by Dox with or without OA were further incubated for 48 h and processed for western blotting with Bax, Bcl-2
and PARP antibodies. (B) HTet23p53, HTet26p53 and HeLa cells were treated as mentioned in (A) and incubated with mitotracker deep-red. Cells
were fixed and processed for immunofluorescence with Bax antibody. Bar:10 μm. Lower panel shows magnified-view for HTet23p53 cells. (C)
HTet23p53 cells were treated as described in (A) and processed for mitochondrial and cytoplasmic fractionation. Western blotting was performed
with cytochrome-C antibody. (D) HTet23p53 cells transfected with pTRE or pTREBcl-2 plasmids were treated with 500 ng/ml of Dox for 48 h and
processed for western blotting with Bcl-2 specific antibody. b-Actin served as a loading control (inset). HTet23p53, HTet26p53, HTet43GFP and HeLa
cells were transfected with pTRE or pTRE2Bcl-2 plasmids and treated with Dox with or without OA and further incubated for 48 h. Cell-viability was
determined by MTT. Bars represent variation within the wells of an experiment done twice (± S.E.). *Represents P < 0.01.
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under non-stressed conditions. Cdk5 was originally dis-
covered in HeLa cells [36] and its functional role as p53
upstream kinase has been documented in neuronal cells
[37]. Involvement of Cdk5 in growth of breast and pros-
tate cancers cells has been reported [38-40]. Recently,
we reported that Cdk5 transactivates p53 in breast can-
cer cells under positive regulation of ERK following car-
boplatin treatment [40]. Cdk5-inhibition promotes
survival of p53 expressing cells. As PP2A-inhibition
restores the ability of overexpressed p53 to promote
cell-death, the upstream kinase that phosphorylates
overexpressed p53 under non-stress conditions was
investigated. In the present study we demonstrate that
p35, a Cdk5 activator levels diminishes following inhibi-
tion of PP2A and simultaneous increase in the levels of
more sustainable Cdk5 activator p25 following p35 clea-
vage [41]. Thus, increased level of Cdk5 activator (p25)
may facilitate Cdk5-mediated phosphorylation of overex-
pressed p53, which causes cell-growth inhibition. The
decreased level of p35 protein in HTet43GFP cells does
not cause cell-growth inhibition because of unavailability
of its substrate (in this model overexpressed p53).
Though, Cdk5 plays an important role in activating
overexpressed p53, as such it is not involved in the pro-
liferation of parental HeLa cells per se in spite of the
fact that E6 expression leads to increase in Cdk5 protein
expression.
p53 executes its apoptotic function through intrinsic or
extrinsic pathways [42,43]. To further confirm the pathway
involved, we investigated Bax, an important transcriptional
target of p53 involved in promoting intrinsic mitochon-
drial apoptosis. Bax translocates to mitochondrial outer
membrane causing MOMP and releases cytochrome-C
into cytosol. Cells lacking Bax or those overexpressing
Bcl-2 are profoundly resistant to a broad range of
Figure 8 Cdk5 associates with p53 to phosphorylate at Ser20 and Ser46. (A) HTet26p53 and HTet43GFP cells 12 h pretreated with Cdk2/5
inhibitor were treated with Dox in the presence or absence of OA for 48 h and processed for western blotting with p53, pSer20 and pSer46
antibodies. (B) HTet26p53 and HTet43GFP cells treated as mentioned in (A) were processed for immunoprecipitation with p53 antibody. p53 and
Cdk5 immunoblot was done. (C) Model for Cdk5-mediated p53 phosphorylation and activation. Cdk5 phosphorylates p53 which is
dephosphorylated by PP2A. Inhibition of PP2A promotes phosphorylation of p53 at Ser20 and Ser46. Activated p53 is recruited on p21 and Bax
promoter to execute cell cycle arrest and apoptosis. Cdk5 phosphorylation is not dependent on ERK activation but on an unknown kinase(s).
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Page 12 of 15apoptotic stimuli, including chemotherapeutic drugs treat-
ment and serum starvation [17]. In HPV-positive cancers
Bcl-2 overexpression and Bax degradation by E6 facilitates
cancer progression [14]. Here, we demonstrate that upre-
gulated Bax translocates to mitochondria upon PP2A-inhi-
bition in p53 overexpressing cells which is dependent on
Cdk5 activity. Thus, only phosphorylated p53 triggers Bax
transcription to increase its levels and cause apoptosis. In
addition, the cell cycle arrest caused by inhibition of PP2A
in p53 overexpressing cells may be dependent on tran-
scriptional upregulation of p21 gene. Collectively these
data also provide evidence for reactivation of E6 disrupted
p21 and Bax pathways in HPV positive cells.
Finally, we propose that Cdk5 interacts with p53 and
phosphorylates Ser20 and Ser46 residues. Phosphoryla-
tion restores the ability of overexpressed p53 to specifi-
cally bind on p21 and bax promoters (Figure 5C). These
findings provide novel insight into the regulation of p53
transactivation functions and propose PP2A to be a key
player in modulating p53 functionality. The phosphory-
lated status of specific residues may be involved in pro-
moter selection and this proposition needs further
investigations. Also, this is the first report which pro-
vides mechanism for functional activation of p53, and
details the essential modifications necessary for non-
genotoxically overexpressed p53 to be able to execute its
tumor suppressor functions in HPV-positive cells. More-
over, activation of overexpressed p53 without targeting
viral oncogenes may have implication in the treatment
of virus infected carcinomas. The efforts towards the
newer approaches to target p53 pathway and usefulness
of reactivation of p53 pathways in treatment of cancers
are encouraging. Therefore, these findings could have
therapeutic importance for the treatment of cervical
cancers as well as other cancers types in which p53 is
functionally abrogated.
Figure 9 Activated p53 inhibits tumor-growth by transcriptional activation of its downstream pathways. (A) HTet23p53 (n = 12 mice) or
HTet43GFP (n = 4 mice bearing 2 tumors each) were divided in two groups and one group was given water supplemented with Dox. After
tumor size reached to 5-10 mm in diameter, OA was administered to all mice. Tumor-growth was measured weekly and average tumor volume
was plotted (+S.E.). *Represents P < 0.05. (B) Tumor image and weight after mice were sacrificed. (C) Western blotting of p53 and bax and (D)
RT-PCR for p53 was performed in HTet23p53 and HTet43GFP tumors samples from mice with or without access to Dox in the presence and
absence of OA. b-actin loading control. (E) Tumors samples from mice given Dox with or without OA treatment were processed for ChIP assay.
Input and eluted DNA was used for RT-PCR with p21 or bax promoter primers.
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Additional file 1: Material and methods. File contains material,
methods and references pertaining to additional files 2, 3, 4, 5.
Additional file 2: Verification and screening for Tet-On responsive
p53/GFP clones. (A) For screening of Tet-On as well as pTREp53
transfected cells, clones (HeLa-Tet-On-p53 numbered 21 to 44) were
treated with 2000 ng/ml Dox for 48 h and processed for western
blotting with p53 specific antibody. b-Actin served as a loading control.
Two clones with low leaky and high inducible expression, HeLa-Tet-On-
p53 23 and 26, were selected for further studies. (B) Screening for Tet-On
regulated GFP clones (HeLa-Tet-On-pBIGFP number 41 to 52) was
performed by incubating cells with 2000 ng/ml Dox for 48 h followed by
observation under fluorescent microscope. One clone HeLa-Tet-On-
pBIEGFP (number 43) having low leaky and high inducible expression
was selected for further studies.
Additional file 3: Growth properties of selected clones did not alter
in comparison to parental HeLa cells and Dox upto 2000 ng/ml is
not significantly toxic to cells. (A) To evaluate viable cells over a period
of 6 days, 2000 cells plated in triplicate in a 96 well plate were stained
with trypan blue. Graphs were plotted with viable cell number vs growth
days. (B) Cells were plated as mentioned in A and lysed for protein
estimation. Graph was plotted with protein concentration vs days. (C)
Ten thousand cells plated in triplicate in a 96 well plate were treated
with indicated concentration of Dox for 48 h and processed for MTT
assay. Graph was plotted with percentage cell survival vs Dox
concentration.
Additional file 4: Overexpressed p53 exhibits nuclear localization.
(A) HTet23p53, (B) HTet26p53 and (D) HeLa cells treated with 100 and
1000 ng/ml of Dox were incubated for 48 h and processed for
immunofluorescence study with p53 specific antibody. HTet23p53,
HTet26p53 and HeLa cells were probed with FITC conjugated (green-
staining). Upper left section of image represents p53 staining (green);
lower left represents DAPI (blue), upper right phase contrast and lower
right (overlay of them). (C) HTet43GFP cells were probed with rhodamine
conjugated (red-staining) 2° antibody. Green staining in HTet43GFP cells
depicts GFP staining. DAPI (blue staining) represents nuclear staining.
Upper left section of image represents GFP (green), upper middle section
represents p53 staining (red), lower left represents DAPI (blue), upper
right phase contrast and lower middle represents (overlay of them).
Bar:10 μm.
Additional file 5: Activated p53 triggers apoptosis. HTet23p53,
HTet26p53 and HeLa cells were plated in a 35 mm plate and pretreated
with Cdk2/5 (10 μM) inhibitor for 12 h. Thereafter 500 ng/ml Dox or 5
nM OA was added for 48 h. Cells were harvested by trypsinization and
processed for TUNEL assay by FACS analysis as per manufacturer’s
instruction with the modification that reaction mixture was incubated for
2 h instead of 1 h.
Abbreviations
CAT: chloramphenicol acetyl transferase; CDK5: cyclin dependent kinase 5;
DOX: doxycycline; OA: okadaic acid; PP2A: protein phosphatase 2A;
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